Stories of CARE: Linette
Triple negative breast cancer is one of the most aggressive forms of breast cancer. For those facing this diagnosis, treatment can be more complex—and the path forward less certain.
Linette’s journey is also a reminder of what’s possible when care is timely, treatment is guided by research, and patients are supported every step of the way.
When the Path Changed
Linette was first diagnosed with stage I triple negative breast cancer in 2016. After surgery, chemotherapy, and radiation, follow-up imaging showed no evidence of disease.
In 2019, new symptoms revealed that her cancer had returned in nearby lymph nodes and the sternum.
She began chemotherapy and participated in the All4Cure study, designed to help guide more personalized treatment decisions. Her care also included immunotherapy, additional radiation, oral therapy, and supportive treatment.
Over time, her scans improved. By 2020, imaging showed no evidence of active disease.
Since then, Linette has remained in remission, with ongoing follow-up showing no signs of recurrence as of 2026.
Her experience reflects how access to research and evolving treatment options can change the course of care.
Expanding What’s Possible
Triple negative breast cancer accounts for only 10–15% of diagnoses, but it carries a higher risk of recurrence—especially when it spreads beyond the breast.
For patients with metastatic disease, long-term outcomes have historically been difficult. But those numbers don’t tell the full story.
Linette’s experience shows what can happen when patients have access to:
Timely, coordinated treatment
Research-driven care, including studies like All4Cure
Advanced tools that support ongoing monitoring
Long-term follow-up and personalized care
Together, these elements are creating new opportunities for patients facing complex diagnoses.
The Role of Donor Support
Progress like this happens through continued investment in research and patient care.
Philanthropy expands access to clinical trials, advances new treatment approaches, and supports tools that can detect recurrence earlier—while ensuring patients receive the long-term follow-up they need.
For patients like Linette, these efforts help turn possibility into real outcomes.